Items where authors include "Ory, B."

Article

Grünewald, T.G.P., Alonso, M., Avnet, S. et al. (39 more authors) (2020) Sarcoma treatment in the era of molecular medicine. EMBO Molecular Medicine, 12 (11). e11131. ISSN 1757-4676

Moukengue, B., Brown, H.K., Charrier, C. et al. (11 more authors) (2020) TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model. EBioMedicine, 53. 102704. ISSN 2352-3964

Tellez-Gabriel, M., Ory, B., Lamoureux, F. et al. (2 more authors) (2016) Tumour heterogeneity: the key advantages of single-cell analysis. International Journal of Molecular Sciences, 17 (12). 2142. ISSN 1661-6596

Rodriguez Calleja, L., Jacques, C., Lamoureux, F. et al. (13 more authors) (2016) ΔNp63α silences a microRNA program to aberrantly initiate a wound healing program that promotes TGFβ-induced metastasis. Cancer Research, 76 (11). pp. 3236-3251. ISSN 0008-5472

Ory, B., Baud'huin, M.E., Verrecchia, F. et al. (7 more authors) (2016) Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression. Clinical Cancer Research, 22 (10). pp. 2520-2533. ISSN 1078-0432

Jacques, C., Lamoureux, F., Baud'huin, M. et al. (8 more authors) (2016) Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Oncotarget. ISSN 1949-2553

Gabriel, M.T., Calleja, L.R., Chalopin, A. et al. (2 more authors) (2016) Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. Clinical Chemistry, 62 (4). pp. 571-581. ISSN 0009-9147

Jacques , C., Rodriguez-Calleja, L., Baud'huin, M. et al. (4 more authors) (2016) miRNA-193a-5p of p73 controls cisplatin chemoresistance in primary bone tumors. Oncotarget, 7. pp. 54503-54514. ISSN 1949-2553

Gobin, B., Baud'Huin, M., Lamoureux, F. et al. (8 more authors) (2015) BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. International Journal of Cancer, 136 (4). pp. 784-796. ISSN 0020-7136

Lamoureux, F., Baud'huin, M., Ory, B. et al. (5 more authors) (2014) Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. Oncotarget, 5 (17). pp. 7805-7819. ISSN 1949-2553

Gobin, B., Battaglia, S., Lanel, R. et al. (5 more authors) (2014) NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Letters, 344 (2). pp. 291-298. ISSN 0304-3835

Gobin, B., Moriceau, G., Ory, B. et al. (5 more authors) (2014) Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models. PLoS ONE, 9 (3). e90795. ISSN 1932-6203

Lamoureux, F., Baud'huin, M., Calleja, L.R. et al. (7 more authors) (2014) Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. NATURE COMMUNICATIONS, 5. ARTN 3511. ISSN 2041-1723

Moriceau, G., Ory, B., Mitrofan, L. et al. (11 more authors) (2010) Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process. Cancer Research, 70 (24). pp. 10329-10339. ISSN 0008-5472

Moriceau, G., Ory, B., Gobin, B. et al. (5 more authors) (2010) Therapeutic Approach of Primary Bone Tumours by Bisphosphonates. Current Pharmaceutical Design, 16 (27). pp. 2981-2987. ISSN 1381-6128

Ory, B., Moriceau, G.D., Trichet, V. et al. (5 more authors) (2008) Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med, 12 (3). pp. 928-941. ISSN 1582-1838

Lamoureux, F., Ory, B., Battaglia, S. et al. (6 more authors) (2008) Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. International Journal of Cancer, 122 (4). pp. 751-760. ISSN 0020-7136

Ory, B., Blanchard, F., Battaglia, S. et al. (3 more authors) (2007) Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Molecular Pharmacology, 71 (1). pp. 333-343. ISSN 0026-895X

Ory, B., Moriceau, G., Redini, F. et al. (1 more author) (2007) mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: Bi-functional compounds for the treatment of bone tumours. Current Medicinal Chemistry, 14 (13). pp. 1381-1387. ISSN 0929-8673

Gouin, F., Ory, B., Redini, F. et al. (1 more author) (2006) Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. International Journal of Cancer, 119 (5). pp. 980-984. ISSN 0020-7136

Ory, B., Heymann, M.F., Kamijo, A. et al. (3 more authors) (2005) Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer, 104 (11). pp. 2522-2529. ISSN 0008-543X

Heymann, D. orcid.org/0000-0001-7777-0669, Ory, B., Blanchard, F. et al. (7 more authors) (2005) Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone , 37 (1). pp. 74-86. ISSN 8756-3282

Heymann, D. orcid.org/0000-0001-7777-0669, Ory, B., Gouin, F. et al. (2 more authors) (2004) Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends in Molecular Medicine, 10 (7). pp. 337-343. ISSN 1471-4914